Sort
23,748 grants matching “melanoma”
A clinical decision support tool to understand the survival benefit of kidney transplantation in candidates with a history of cancer
$348,657Allyson Hart · Hennepin Healthcare Research Institute · R01 · FY2024 · DK
Targeting the developmental pathways Notch and ERBB for melanoma therapy
$348,616Barbara Bedogni · Case Western Reserve University · R01 · FY2016 · CA
GPCR - Linked RhoGEFs in Tumor Growth and Metastasis
$348,611John J G Tesmer · Purdue University · R01 · FY2022 · CA
Enhancing CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
$348,609Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2020 · CA
POLYAMINE ANALOG REGULATION OF CELL CYCLE AND APOPTOSIS
$348,607Roswell Park Cancer Institute Corp · R01 · FY2004 · CA
Interferon-gamma limits the effectiveness of peptide vaccines for cancer
$348,600Esteban Celis · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2012 · CA
POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
$348,600New York University School Of Medicine · R01 · FY2001 · CA
The CD93 pathway and melanoma therapy
$348,592Yuwen Zhu · University Of Colorado Denver · R01 · FY2023 · CA
Cancer and Leukemia Group B
$348,584Eric P Winer · Dana-Farber Cancer Inst · U10 · FY2008 · CA
The Synthesis and Bioassay of Novel Pyrroles
$348,572John T. Gupton · University Of Richmond · R15 · FY2012 · CA
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
$348,498Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2014 · CA
Targeting Abl kinases in BRAF-driven melanomas
$348,484Rina Plattner · University Of Kentucky · R01 · FY2020 · CA
Targeting Abl kinases in BRAF-driven melanomas
$348,484Rina Plattner · University Of Kentucky · R01 · FY2021 · CA
Analysis of the role of the SWI/SNF complex in tumor suppression
$348,478Charles W Roberts · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Genome-wide association study of cutaneous squamous cell carincoma
$348,477Maryam Mandana Asgari · Massachusetts General Hospital · R01 · FY2015 · CA
Metabolic Vulnerabilities in Melanoma Tumors
$348,404Pere Puigserver · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Molecular Basis for p70S6 Kinase and JARID1B Demethylase Activity and Inhibition
$348,384Ronen Marmorstein · Wistar Institute · P01 · FY2013 · CA
IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
$348,348University Of Southern California · R01 · FY2002 · CA
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
$348,312Aleksandar None Sekulic · Mayo Clinic Arizona · R01 · FY2017 · CA
MET Activation in Melanoma Genesis and Progression
$348,250Lynda Chin · Dana-Farber Cancer Inst · R01 · FY2006 · CA
PHOTODYNAMIC THERAPY (PDT) AND TUMOR IMMUNITY
$348,228Sandra O Gollnick · Roswell Park Cancer Institute Corp · R01 · FY2009 · CA
Generating a Systemic Immune Response Using Localized Delivery of Chemotherapy in Brain Tumors
$348,202Michael Lim · Stanford University · R01 · FY2024 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$348,182Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA
Targeting ROS by a p53-activating agent for selective killing of cancer cells
$348,111Sam W Lee · Massachusetts General Hospital · R01 · FY2011 · CA
Targeting ROS by a p53-activating agent for selective killing of cancer cells
$348,111Sam W Lee · Massachusetts General Hospital · R01 · FY2012 · CA